Natixis Advisors LLC Sells 57,151 Shares of Stryker Corporation $SYK

Natixis Advisors LLC lessened its position in shares of Stryker Corporation (NYSE:SYK) by 25.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 165,181 shares of the medical technology company’s stock after selling 57,151 shares during the period. Natixis Advisors LLC’s holdings in Stryker were worth $58,056,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after buying an additional 133,892 shares during the last quarter. Geode Capital Management LLC raised its stake in Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after buying an additional 69,851 shares during the last quarter. Alliancebernstein L.P. raised its stake in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares during the last quarter. Norges Bank bought a new position in Stryker during the fourth quarter worth $1,822,272,000. Finally, Legal & General Group Plc raised its stake in Stryker by 2.7% during the fourth quarter. Legal & General Group Plc now owns 2,366,107 shares of the medical technology company’s stock worth $831,616,000 after buying an additional 62,817 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.8%

SYK opened at $295.63 on Thursday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a market cap of $113.33 billion, a P/E ratio of 34.22, a price-to-earnings-growth ratio of 1.85 and a beta of 0.78. The company has a fifty day moving average price of $319.41 and a two-hundred day moving average price of $346.58.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same period last year, the firm posted $2.84 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s payout ratio is presently 40.74%.

Analyst Ratings Changes

SYK has been the subject of a number of analyst reports. BTIG Research lowered their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Citigroup decreased their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday, May 1st. Finally, Leerink Partners assumed coverage on shares of Stryker in a research note on Monday, April 13th. They issued an “outperform” rating and a $410.00 price target for the company. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $395.48.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president directly owned 177 shares of the company’s stock, valued at approximately $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 over the last three months. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.